Ramos Guarderas Pablo, Arteaga Guerrero Gonzalo, Vargas Morante Medardo, Ramos Murrillo Pablo, Peñaherrera Carrillo Carlos, Endara Urresta Francisco, Ramos Murillo Daniel, Barros Castro Alejandro, Vaca Perez Paul
Clinica Arthros, Quito, Pichincha, Ecuador.
Quiron Salud, Madrid, Madrid, Spain.
Arthroplast Today. 2025 Jul 15;34:101735. doi: 10.1016/j.artd.2025.101735. eCollection 2025 Aug.
Isolated patellofemoral osteoarthritis is a frequent source of anterior knee pain in middle-aged patients. Second-generation onlay patellofemoral prostheses were developed to address limitations of earlier designs and improve clinical outcomes.
We conducted a retrospective study of 231 patients (mean age 52.2 years) who underwent patellofemoral arthroplasty with a second-generation onlay implant between 2009 and 2023. Clinical outcomes were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index and Kaplan-Meier survival analysis. Radiological evaluation included signs of loosening, progression of tibiofemoral osteoarthritis, and patellar alignment.
At a mean follow-up of 9.3 years (range: 2-14), Western Ontario and McMaster Universities Osteoarthritis Index scores improved significantly from 92.14 to 8.40 ( < .001). The implant survival rate was 96.6% at the final follow-up. Early clinical gains were significantly influenced by implant type, while long-term outcomes were associated with patient-specific factors such as body mass index and activity level. Radiological progression of tibiofemoral disease was observed in 6.1% of patients.
Second-generation onlay patellofemoral prostheses yield sustained functional improvement and low complication rates when used in carefully selected patients. These findings support their use as a reliable solution for isolated patellofemoral osteoarthritis.
III.
孤立性髌股关节炎是中年患者膝前疼痛的常见原因。第二代嵌体式髌股假体的研发旨在解决早期设计的局限性并改善临床疗效。
我们对2009年至2023年间接受第二代嵌体式植入物髌股关节置换术的231例患者(平均年龄52.2岁)进行了一项回顾性研究。使用西安大略和麦克马斯特大学骨关节炎指数以及Kaplan-Meier生存分析评估临床疗效。影像学评估包括松动迹象、胫股关节炎进展情况以及髌骨对线情况。
平均随访9.3年(范围:2至14年)时,西安大略和麦克马斯特大学骨关节炎指数评分从92.14显著改善至8.40(P <.001)。末次随访时植入物生存率为96.6%。早期临床获益受植入物类型的显著影响,而长期疗效与体重指数和活动水平等患者个体因素相关。6.1%的患者观察到胫股疾病的影像学进展。
第二代嵌体式髌股假体用于精心挑选的患者时,可带来持续的功能改善且并发症发生率低。这些发现支持将其作为孤立性髌股关节炎的可靠解决方案。
III级